Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oscar Health’s filings can run hundreds of pages, packed with medical loss ratio math, state-by-state premium detail, and technology capitalization rules—enough to overwhelm even seasoned analysts. If you have ever asked, “How do I find Oscar Health’s quarterly earnings report 10-Q filing?” or searched for “Oscar Health insider trading Form 4 transactions,” you know the challenge.
Stock Titan solves it. Our AI reads every 10-K, 10-Q, 8-K, and proxy the moment they post to EDGAR, then delivers plain-English explanations. Want the cash-burn trend without scanning footnotes? Need Form 4 insider transactions real-time to see when executives buy shares? Curious about how Oscar’s telehealth investment shows up in the annual report 10-K simplified? One click, instant clarity.
Here is what you can track today:
- Revenue and membership shifts in each Oscar Health SEC filings explained simply
- Oscar Health executive stock transactions Form 4 with real-time alerts
- Oscar Health proxy statement executive compensation breakdowns
- Material policy updates via Oscar Health 8-K material events explained
- Quarterly results through the Oscar Health earnings report filing analysis
Because filings update fast, our platform refreshes the moment a document hits EDGAR, ensuring you never miss an 8-K about a new state license or a Form 4 hinting at insider confidence. Understanding Oscar Health SEC documents with AI means spending minutes, not hours, to uncover the metrics that move premiums, profitability, and your investment decisions.
Oscar Health, Inc. (OSCR) has filed a Form 144 indicating a planned sale of 30,000 common shares through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units (RSUs) on 06/01/2024 and are slated for sale on or about 06/20/2025 on the NYSE. Based on the stated aggregate market value of $563,100, the implied price is roughly $18.77 per share. With 219.163 million shares outstanding, the transaction represents only about 0.014 % of total shares, suggesting minimal dilution or market impact. No other sales by the filer occurred in the past three months, and no adverse information was disclosed in the notice.